Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Janny M. Yao
Observed name:
Janny Yao
Institution:
City Of Hope National Medical Center
Observed institutions:
City Of Hope National Medical Center,
City of Hope
ORCID:
0009-0004-6817-7248
Observed ORCID:
0009-0004-6817-7248
OpenAlex ID:
A5068612081
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
2023
·
Javier Bolaños-Meade
, Mehdi Hamadani
, et al.
·
New England Journal of Medicine
·
673
PDF
Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
2022
·
Shernan G Holtan
, Mehdi Hamadani
, et al.
·
Blood
·
62
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703
2025
·
Sameem Abedin
, Michael J. Martens
, et al.
·
Blood Advances
·
17
PDF
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703
2025
·
Shernan G. Holtan
, Javier Bolaños-Meade
, et al.
·
Journal of Clinical Oncology
·
13
PDF
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis
2023
·
Janny M. Yao
, Salman Otoukesh
, et al.
·
Transplantation and Cellular Therapy
·
11
Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens
2021
·
Janny M. Yao
, Dongyun Yang
, et al.
·
Bone Marrow Transplantation
·
9
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis
2025
·
Diana T. Samuels
, Janny M. Yao
, et al.
·
Frontiers in Immunology
·
5
PDF
Eculizumab Treatment Outcomes in Patients with Allogeneic Hematopoietic Cell Transplant (alloHCT)-Associated Thrombotic Microangiopathy (TA-TMA): A Retrospective Single-Center Experience
2024
·
Yazeed Samara
, Janny Yao
, et al.
·
Transplantation and Cellular Therapy
·
3
Use of monoclonal antibody therapy in hematologic patients with mild‐to‐moderate COVID ‐19: A retrospective single‐center experience
2023
·
Idoroenyi Amanam
, Janny Yao
, et al.
·
Cancer Medicine
·
3
PDF
Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
2024
·
Sameem Abedin
, Qinghua Lian
, et al.
·
Blood
·
2
Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience
2021
·
Idoroenyi Amanam
, Janny M. Yao
, et al.
·
Blood
·
2
PDF
Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation
2023
·
Shernan G. Holtan
, Michael J Martens
, et al.
·
Blood
·
1
Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
2022
·
Janny M. Yao
, Hanna Kim
, et al.
·
Blood
·
1
Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis
2019
·
Janny M. Yao
, Dongyun Yang
, et al.
·
Blood
·
1
Show more works
View as search
Works count:
14
Citation count:
803
H-index:
6
I10-index:
5
Year
Topic
Type